Parenteral Manual


Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Antidote, Extravasation
Original Date: 
October 2013
Revised Date: 
December 2020
  • Management of IV extravasation
Reconstitution and Stability: 
  • Available as a 150 units/mL 2mL vial
  • Store unopened vials refrigerated (2-8°C)

-  Solutions Compatible:  D5W, D10W, 0.45% NaCl, 0.9% NaCl, Ringer's solution, Ringer's lactate


(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

IV Push NO
IV Intermittent
IV Continuous




(For neonatal dosages, refer to Neonatal IV Drug Manual.)

  • Attach a 25 or 27 gauge needle to the syringe and administer 0.2 mL subcutaneously into the leading edge of the extravasation.  Remove needle and apply new 25 or 27 gauge needle for each 0.2 mL injection around the site
  • Administer a total of 150 units (5 x 0.2 mL injections) subcutaneously into the extravasation site at the leading edge
  • A dose of 300 units (10 x 0.2 mL or 5 x 0.4 mL injections) can be used for large infiltrates of grade +2 or greater
  • Use within 1 hour of extravasation for maximal effect
  • Must be given within 4 hours of infiltration


Potential hazards of parenteral administration: 
  • Hyaluronidase is NOT for intravenous administration
  • DO NOT inject into tumors, acute inflamed or infected areas
  • Hyaluronidase has an immediate onset of action and a 24 - 48 hour duration of effect
  • Corticosteroids may worsen toxicity
  • Toxicity of hyaluronidase is NOT increased by the use of a cold pack
  • Side effects:  local swelling may occur.  Urticaria and erythema possible

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.